Mounjaro Better for Weight Loss Than Ozempic, Study Finds
A new study has found that Mounjaro, a medication used to treat type 2 diabetes and obesity, outperforms Ozempic in weight loss outcomes. The study, published in JAMA Internal Medicine, compared the effectiveness of Mounjaro (tirzepatide) and Ozempic (semaglutide) in a real-world setting using healthcare data.
Study Highlights
The study found that patients taking Mounjaro were more likely to achieve a weight loss of 10% or greater and three times as likely to achieve a weight loss of 15% or greater compared to patients taking Ozempic. Total weight loss at various intervals, including three, six, and 12 months, was also greater among those taking Mounjaro.
Weight Loss Results
The study found that:
- Patients taking Mounjaro were more than twice as likely to achieve a weight loss of 10% or greater.
- Patients taking Mounjaro were three times as likely to achieve a weight loss of 15% or greater.
- Total weight loss at three months was 5.9% for Mounjaro and 3.6% for Ozempic.
- Total weight loss at one year was 15.2% for Mounjaro and 8.1% for Ozempic.
Safety Profile
The study also compared the safety profiles of the two medications, finding that both Mounjaro and Ozempic resulted in similar rates of adverse gastrointestinal events, including nausea, diarrhea, and vomiting. More serious complications, such as bowel obstruction or ileus, were also observed, but at similar rates for both medications.
Study Design
The study used electronic health records and prescriber data from Truveta, a healthcare data and analytics company. The study included adults with overweight or obesity who began taking either Mounjaro or Ozempic for the first time between May 2022 and September 2023. Patients who had previously taken a GLP-1 drug were excluded from the study.
Conclusion
This study provides evidence that Mounjaro is more effective than Ozempic in weight loss outcomes in a real-world setting. The findings suggest that Mounjaro may be a more effective treatment option for patients with obesity and type 2 diabetes.
FAQs
Q: What were the main findings of the study?
A: The study found that patients taking Mounjaro were more likely to achieve a weight loss of 10% or greater and three times as likely to achieve a weight loss of 15% or greater compared to patients taking Ozempic.
Q: What were the safety profiles of the two medications?
A: The study found that both Mounjaro and Ozempic resulted in similar rates of adverse gastrointestinal events, including nausea, diarrhea, and vomiting.
Q: What were the limitations of the study?
A: The study was conducted using electronic health records and prescriber data, which may not capture all aspects of patient care. Additionally, the study excluded patients who had previously taken a GLP-1 drug.
Q: What does this study mean for patients with obesity and type 2 diabetes?
A: This study suggests that Mounjaro may be a more effective treatment option for patients with obesity and type 2 diabetes. Patients should discuss their treatment options with their healthcare provider to determine the best course of treatment for their individual needs.
Recommended Products:
-
Life Extension Two-Per-Day High Potency Multi-Vitamin & Mineral Supplement – Vitamins, Minerals, Plant Extracts, Quercetin, 5-MTHF Folate & More – Gluten-Free – Non-GMO – 120 Tablets
$18.38 Buy Now -
Sale!
NOW Supplements, Vitamin C-1,000 with 100 mg of Bioflavonoids, Antioxidant protection*, 100 Veg Capsules
Original price was: $13.99.$8.56Current price is: $8.56. Buy Now -
Sale!
NOW Supplements, NAC (N-Acetyl-Cysteine) 1,000 mg, Free Radical Protection*, 120 Tablets
Original price was: $34.99.$19.18Current price is: $19.18. Buy Now
